Racial Disparities Associated with Maternal Exposure to Environmental Endocrine Disrupting Compounds in a Southeastern U.S. Community

项目摘要 目的：我们提出了一项前瞻性队列研究，以检查妊娠对胎儿发育的影响。 非裔美国人暴露于内分泌干扰物环境酚（EPs）和邻苯二甲酸酯（PHTs） (AA)和白色母亲在美国东南部的产科人口。重点将放在如何协会 胎儿发育结果的EP因种族而异。我们还将探讨如何共同暴露于EP和 PHTs影响这些协会。 意义：这项拟议中的研究将从根本上推进我们对种族差异的理解， 暴露于EP以及这些差异如何导致AA之间的生殖健康差异 还有白人我们还将探讨妊娠期共同暴露于EP和EP的复杂混合物的联合作用。 对胎儿发育有影响。这项研究直接解决了我们在理解影响方面的重大差距， 高度流行的EP和PTs对AA中胎儿发育的影响，并为更明确的 今后研究混合内分泌干扰物暴露对生殖健康差异的影响。 创新：拟议的研究将是第一个利用AA和白色母亲及其母亲的队列的研究。 新生儿，以直接评估妊娠期暴露于EP和PHTs的混合物与胎儿的健康差异 发展成果。这将是为数不多的研究之一，以评估混合妊娠暴露的影响， EP和PTs以及第一个在美国东南部捕获这些数据的人，其中， 在美国，AA和白人之间的早产和低出生体重是最高的。 初步研究：该建议建立在一项对8种常见泌尿系结核性甲状腺炎的前瞻性队列研究的基础上， 在南卡罗来纳州的查尔斯顿的AA和白色母亲中先前测量的胎儿发育。的 结果有力地支持了所概述的方法，特别是关于种族的不同影响。 方法：AA（n=152）和白色（n=158）母婴对在2011-2014年间完成了我们的研究。 参与者提供了妊娠期和分娩时的尿液和血液标本， 胎儿超声，完成了关于暴露源的研究问卷，并同意病历 access.我们将测量10个流行的EP在存档的母亲尿液和相关的浓度与出生 妊娠中期和分娩时超声检查的结果、新生儿肛门生殖器距离和阴茎尺寸。 我们将探讨共同暴露于EP和PHTs的影响，以及这些结果如何因种族而异。成功 我们的项目的完成是由团队的经验，谁一起工作，以完成 以前的项目，并在产科，生殖内分泌学，分析 化学、流行病学和生物统计建模。这些数据将用于开发R 01应用程序， 支持未来进行更全面、更机械的研究，以解决这一重要的生物医学研究 关于胎儿暴露于内分泌干扰化合物对种族不同发育影响的空白。

PROJECT SUMMARY Aims: We propose a prospective cohort study to examine fetal developmental effects from gestational exposure to endocrine disrupting environmental phenols (EPs) and phthalates (PHTs) in African American (AA) and white mothers in a southeastern U.S. obstetrical population. The focus will be on how associations of EPs with fetal developmental outcomes vary by race. We will also explore how co-exposure to both EPs and PHTs influence these associations. Significance: The proposed study will fundamentally advance our understanding of racial disparities in exposure to EPs and how these differences may contribute to reproductive health disparities between AAs and whites. We will also explore the joint effects of gestational co-exposure to a complex mixture of EPs and PHTs on fetal development. This study directly addresses significant gaps in our understanding the impact of highly prevalent EPs and PHTs on fetal development among AAs and lays the foundation for a more definitive future study of the effect of mixed endocrine disrupting exposures on reproductive health disparities. Innovation: The proposed study will be the 1st to leverage a cohort of AA and white mothers and their newborns, to directly assess health disparities in gestational exposure to a mixture of EPs and PHTs with fetal developmental outcomes. It will be one of few studies to assess the impact of mixed gestational exposure to EPs and PHTs and the 1st to capture these data in the southeastern U.S., where disparities in rates of prematurity and low birth weight between AAs and whites is the highest in the U.S. Preliminary Study: This proposal builds upon a prospective cohort study of 8 prevalent urinary PHTs that we previously measured and fetal development among AA and white mothers in Charleston, South Carolina. The results provide strong support for the approach outlined, especially in regard to differential effects by race. Approach: AA (n=152) and white (n=158) mother-infant pairs completed our study between 2011-2014. Participants provided urine and blood specimens during gestation and at delivery, had a detailed mid-gestation fetal ultrasound, completed a study questionnaire about exposure sources and consented to medical records access. We will measure 10 prevalent EPs in archived maternal urine and correlate the concentrations to birth outcomes, newborn anogenital distances and penis dimensions by mid-gestation ultrasound and at delivery. We will explore the impact of co-exposure to EPs and PHTs and how these results vary by race. Successful completion of our project is ensured by the experience of the team, who worked together to complete the previous project, and have the necessary expertise in obstetrics, reproductive endocrinology, analytic chemistry, epidemiology and biostatistical modeling. These data will be used to develop an R01 application to support a more comprehensive and mechanistic future study to address this important biomedical research gap regarding racially disparate developmental effects of fetal exposure to endocrine disrupting compounds.